Overview

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Status:
RECRUITING

Trial end date:
2028-01-01

Target enrollment:

Participant gender:

Summary

This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.

Phase:

PHASE1

Details

Lead Sponsor:

Auricula Biosciences Inc.

Collaborator:

Simbec-Orion Group